Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Research Article

Formulation, Optimization and Characterization of Bupropion Hydrochloride Loaded Nanostructured Lipid Carriers for Intra-Nasal Administration: An Approach to Management of Smoking Cessation

Author(s): Aravind Shyamprasad Rekharani, Bala Sai Soujith Nidamanuri, Praharsh Kumar Mandadhi Rajendra, Senthil Venkatachalam, Jubie Selvaraj and Jawahar Natarajan*

Volume 12, Issue 3, 2022

Published on: 08 November, 2022

Page: [217 - 232] Pages: 16

DOI: 10.2174/2468187313666221020143555

Price: $65

Abstract

Background: Tobacco smoking is a major factor leading to cardiovascular diseases. About 48% of cardiovascular diseases occur due to cigarette smoking. Bupropion hydrochloride is a non-nicotine treatment for smoking cessation. The existing marketed formulation of bupropion has limitations, like low bioavailability and extensive first-pass metabolism. In order to boost the bioavailability and increase the brain biodistribution of the drug, a colloidal drug delivery system, like nanostructured lipid carriers, is employed.

Methods: NLC formulation was prepared using the microemulsion technique and an optimized formula was developed using a three-level factorial design.

Results: The particle size of the optimized formulation was 162 nm, the polydispersity index was 12.2%, and the zeta potential was -29.0mV. Entrapment efficiency was found to be 41.2%. SEM images show that these NLCs are spherical. In vitro drug release study was conducted, and at the end of 72 hours, 50% of the drug was released, indicating the sustained release of the drug. Histopathological studies were conducted using goat nasal mucosa, and results indicated the NLC formulation as non-toxic for intranasal administration.

Conclusion: Thus, through the intra-nasal route, an increased concentration of drug can be delivered to the brain via the olfactory pathway, thereby improving the therapeutic effect and exhibiting better patient compliance in smoking cessation.

Keywords: Nanostructured lipid carriers, intra-nasal delivery, bupropion hydrochloride, optimization, smoking cessation, cardiovascular diseases.

Graphical Abstract
[1]
Doll R. Uncovering the effects of smoking: Historical perspective. Stat Methods Med Res 1998; 7(2): 87-117.
[http://dx.doi.org/10.1177/096228029800700202] [PMID: 9654637]
[2]
Kalkhoran S, Benowitz NL, Rigotti NA. Prevention and treatment of tobacco use. J Am Coll Cardiol 2018; 72(9): 1030-45.
[http://dx.doi.org/10.1016/j.jacc.2018.06.036] [PMID: 30139432]
[3]
Carrick MA, Robson JM, Thomas C. Smoking and anaesthesia. BJA Educ 2019; 19(1): 1-6.
[http://dx.doi.org/10.1016/j.bjae.2018.09.005] [PMID: 33456847]
[4]
Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis 2008; 3(1): 45-53.
[http://dx.doi.org/10.2147/COPD.S1121] [PMID: 18488428]
[5]
Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict Biol 2005; 10(3): 219-31.
[http://dx.doi.org/10.1080/13556210500222670] [PMID: 16109583]
[6]
Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: Integrative overview of relevant clinical and forensic aspects. Drug Metab Rev 2019; 51(3): 293-313.
[http://dx.doi.org/10.1080/03602532.2019.1620763] [PMID: 31124380]
[7]
kaur S, Nautyal U, Singh R, Singh S, Devi A. Nanostructure Lipid Carrier (NLC): The new generation of lipid nanoparticles. Asian Pac J Health Sci 2015; 2(2): 76-93.
[http://dx.doi.org/10.21276/apjhs.2015.2.2.14]
[8]
Illum L. Nasal drug delivery: New developments and strategies. Drug Discov Today 2002; 7(23): 1184-9.
[http://dx.doi.org/10.1016/S1359-6446(02)02529-1] [PMID: 12547019]
[9]
Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: Current status and future perspective. Drug Deliv 2014; 21(2): 75-86.
[http://dx.doi.org/10.3109/10717544.2013.838713] [PMID: 24102636]
[10]
Abo El-Enin HA, Elkomy MH, Naguib IA, et al. Lipid nanocarriers overlaid with chitosan for brain delivery of berberine via the nasal route. Pharmaceuticals 2022; 15(3): 281.
[http://dx.doi.org/10.3390/ph15030281] [PMID: 35337079]
[11]
Sharma N, Bhandari S, Deshmukh R, Yadav AK, Mishra N. Development and characterization of embelin-loaded nanolipid carriers for brain targeting. Artif Cells Nanomed Biotechnol 2017; 45(3): 409-13.
[http://dx.doi.org/10.3109/21691401.2016.1160407] [PMID: 27012597]
[12]
Costa CP, Barreiro S, Moreira JN, et al. In vitro studies on nasal formulations of nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN). Pharmaceuticals 2021; 14(8): 711.
[http://dx.doi.org/10.3390/ph14080711] [PMID: 34451808]
[13]
Khan SR, Berendt RT, Ellison CD, Ciavarella AB, Asafu-Adjaye E, Khan MA. Chapter One - Bupropion Hydrochloride. In: Profiles of Drug Substances, Excipients and Related Methodology. Elsevier 2016; 41: pp. 1-30.
[http://dx.doi.org/10.1016/bs.podrm.2015.12.001]
[14]
Pani NR, Nath LK, Acharya S, Bhuniya B. Application of DSC, IST, and FTIR study in the compatibility testing of nateglinide with different pharmaceutical excipients. J Therm Anal Calorim 2012; 108(1): 219-26.
[http://dx.doi.org/10.1007/s10973-011-1299-x]
[15]
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol 2019; 51: 255-67.
[http://dx.doi.org/10.1016/j.jddst.2019.02.017]
[16]
Sood S, Jawahar N, Jain K, Gowthamarajan K, Nainar Meyyanathan S. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Curr Nanosci 2013; 9: 26-34.
[17]
Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010; 394(1-2): 179-85.
[http://dx.doi.org/10.1016/j.ijpharm.2010.05.005] [PMID: 20471464]
[18]
Huang J, Wang Q, Li T, Xia N, Xia Q. Nanostructured lipid carrier (NLC) as a strategy for encapsulation of quercetin and linseed oil: Preparation and in vitro characterization studies. J Food Eng 2017; 215: 1-12.
[http://dx.doi.org/10.1016/j.jfoodeng.2017.07.002]
[19]
Swidan SA, Mansour ZN, Mourad ZA, Elhesaisy NA, Mohamed NA, Bekheet MS. DOE, formulation, and optimization of repaglinide nanostructured lipid carriers. J Anim Plant Sci 2018; 8: 8-16.
[20]
Yao Q, Yang G, Wang H, et al. Aging erythrocyte membranes as biomimetic nanometer carriers of liver-targeting chromium poisoning treatment. Drug Deliv 2021; 28(1): 1455-65.
[http://dx.doi.org/10.1080/10717544.2021.1949075] [PMID: 34236248]
[21]
Dubey A, Prabhu P, Kamath JV. Nano Structured lipid carriers: A Novel Topical drug delivery system. Int J Pharm Tech Res 2012; 4: 705-14.
[22]
Thatipamula R, Palem C, Gannu R, Mudragada S, Yamsani M. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru 2011; 19(1): 23-32.
[PMID: 22615636]
[23]
Özbaş-Turan S, Akbuğa J. Plasmid DNA-loaded chitosan/TPP nanoparticles for topical gene delivery. Drug Deliv 2011; 18(3): 215-22.
[http://dx.doi.org/10.3109/10717544.2010.544688] [PMID: 21226549]
[24]
Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics: A treatise. Vallabh Prakashan 2005.
[25]
Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: Design, characterization, and in vivo study. Drug Deliv 2016; 23(4): 1326-34.
[http://dx.doi.org/10.3109/10717544.2014.975382] [PMID: 25367836]
[26]
Kawtikwar PS, Kulkarni NP, Yadav S, Sakarkar DM. Formulation and evaluation of an anti-epileptic drug-loaded microemulsion for nose to brain delivery. Asian J Pharm 2014; 3.
[27]
Kumar M, Kakkar V, Mishra AK, Chuttani K, Kaur IP. Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood. Int J Pharm 2014; 461(1-2): 223-33.
[http://dx.doi.org/10.1016/j.ijpharm.2013.11.038] [PMID: 24286922]
[28]
Joshi AS, Patel HS, Belgamwar VS, Agrawal A, Tekade AR. Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: Development, optimization and evaluation. J Mater Sci Mater Med 2012; 23(9): 2163-75.
[http://dx.doi.org/10.1007/s10856-012-4702-7] [PMID: 22802103]
[29]
Sood S, Jain K, Gowthamarajan K. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surf B Biointerfaces 2014; 113: 330-7.
[http://dx.doi.org/10.1016/j.colsurfb.2013.09.030] [PMID: 24121076]
[30]
Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res 2010; 20(4): 286-96.
[http://dx.doi.org/10.3109/08982100903443065] [PMID: 19958118]
[31]
Mühlen A, Mühlen E, Niehus H, Mehnert W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm Res 1996; 13(9): 1411-6.
[http://dx.doi.org/10.1023/A:1016042504830] [PMID: 8893284]
[32]
Sandri G, Bonferoni MC, Ferrari F, Rossi S, Caramella CM. The role of particle size in drug release and absorption. In: Particulate Products Particle Technology Series. Cham: Springer 2014; 19: pp. 323-41.
[33]
Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13(2): 123-33.
[http://dx.doi.org/10.1016/S0928-0987(01)00095-1] [PMID: 11297896]
[34]
Ahmed S, Gull A, Alam M, Aqil M, Sultana Y. Ultrasonically tailored, chemically engineered and “QbD” enabled fabrication of agomelatine nanoemulsion; optimization, characterization, ex vivo permeation and stability study. Ultrason Sonochem 2018; 41: 213-26.
[http://dx.doi.org/10.1016/j.ultsonch.2017.09.042] [PMID: 29137746]
[35]
Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater 2011; 7(12): 4169-76.
[http://dx.doi.org/10.1016/j.actbio.2011.07.025] [PMID: 21839863]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy